Silverarc Capital Management’s Rocket Pharmaceuticals RCKT Stock Holding History

Silverarc Capital Management’s Portfolio RCKT Stock Details RCKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-101,002	Closed	-$2.72M	–	84
2024 Q1	$2.72M	Sell	101,002 -281,670	-74%	-$8M	0.76%	42
2023 Q4	$11.5M	Buy	+382,672	New	+$8.45M	3.41%	7
2021 Q3	–	Sell	-10,293	Closed	-$456K	–	100
2021 Q2	$456K	Buy	10,293 +293	+3%	+$12.7K	0.2%	83
2021 Q1	$444K	Hold	10,000	–	–	0.24%	76
2020 Q4	$548K	Buy	+10,000	New	+$365K	0.32%	70

Other funds holding RCKT

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Silverarc Capital Management's RCKT Position: Q2 2024 in Review

Silverarc Capital Management sold out of Rocket Pharmaceuticals (RCKT) in Q2 2024, closing a stake of 101,002 shares — an estimated $2.72M sold.

Silverarc Capital Management first reported a position in RCKT in Q4 2020 and held it in 5 quarters. The position peaked at $11.5M in Q4 2023. 178 funds tracked by Wall St. Rank hold RCKT as of Q2 2024.

Silverarc Capital Management reported no remaining Rocket Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Silverarc Capital Management sold 101,002 Rocket Pharmaceuticals shares in Q2 2024, an estimated $2.72M.
Silverarc Capital Management first reported a position in Rocket Pharmaceuticals in Q4 2020 and held it in 5 quarters.
Silverarc Capital Management's Rocket Pharmaceuticals position peaked at $11.5M in Q4 2023.
178 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2024.

Based on Silverarc Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.